Misplaced Pages

Rafivirumab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

Monoclonal antibody Pharmaceutical compound

Rafivirumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	rabies virus glycoprotein
Clinical data
ATC code	none
Identifiers
CAS Number	944548-37-2
ChemSpider	none
UNII	F6G4126BPE
Chemical and physical data
Formula	C₆₄₆₂H₉₉₅₄N₁₇₁₈O₂₀₃₆S₄₆
Molar mass	145761.46 g·mol
(what is this?) (verify)

Rafivirumab (CR57) is a monoclonal antibody for the prophylaxis of rabies.

References

"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization.
Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, et al. (July 2005). "The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries". European Journal of Immunology. 35 (7): 2131–45. doi:10.1002/eji.200526134. PMID 15971273.
Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, et al. (September 2017). "In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants". Tropical Medicine and Infectious Disease. 2 (3): 48. doi:10.3390/tropicalmed2030048. PMC 6082099. PMID 30270905.

v
t
e

Monoclonal antibodies for infectious disease and toxins

Human	Efungumab

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab Bamlanivimab (+etesevimab) Bebtelovimab Casirivimab (+imdevimab) Cilgavimab (+tixagevimab) Diridavumab Etesevimab Exbivirumab Foravirumab Imdevimab (+casirivimab) Libivirumab Maftivimab Nirsevimab Odesivimab Pemivibart Rafivirumab Regavirumab Regdanvimab Sevirumab Sipavibart Sotrovimab Suptavumab Tixagevimab (+cilgavimab) Tuvirumab
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab
Humanized	Felvizumab Lenvervimab Motavizumab Palivizumab Suvizumab

Human	Nebacumab Panobacumab Raxibacumab
Mouse	Edobacomab
Chimeric	Pagibaximab
Humanized	Tefibazumab

Human	Actoxumab Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

v
t
e

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

v
t
e